05.11.2021 Biotest AG  DE0005227235

DGAP-News: Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.


 

DGAP-News: Biotest AG / Key word(s): Statement
Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

05.11.2021 / 09:46
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

Dreieich, 5 November 2021. Today, the Management Board and the Supervisory Board of Biotest AG ("Biotest") have published their joint reasoned statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz) on the offer document of GRIFOLS, S.A. ("Bidder") dated 26 October 2021. The Biotest works council has given its own statement, which has been published as an annex to the statement of the Management Board and the Supervisory Board.

In this statement, the Management Board and the Supervisory Board recommend, after a careful review process, to the shareholders to accept the offer. This recommendation is explained in more detail in the joint reasoned statement.

After a thorough review, the Management Board and the Supervisory Board have independently come to the conclusion that the consideration offered by the Bidder is fair within the meaning of Section 31 para. 1 WpÜG and that the implementation of the offer is in the interest of Biotest and its shareholders. In assessing the adequacy of the offer from a financial point of view, the Management Board and the Supervisory Board of Biotest were advised by Rothschild & Co. Rothschild & Co concludes in its Fairness Opinion that the offer is fair to Biotest shareholders from a financial point of view.

The Management Board and the Supervisory Board of Biotest see in the business combination a concrete opportunity to combine the existing resources of the Bidder and Biotest in the field of blood plasma in order to achieve a greater availability of resources as well as a larger product range. The Bidder's intended increase of available resources for Biotest's research and development departments could also drive product development and manufacturing faster than would be possible for Biotest as an individual company.

The complete joint reasoned statement of the Management Board and the Supervisory Board of Biotest can be accessed on the company's website at the following link under the heading Investor Relations (in the section "Takeover offer"):

https://www.biotest.com

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: [email protected]

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: [email protected]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



05.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1246482

 
End of News DGAP News Service

1246482  05.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1246482&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 553,10 378,10 400,30 419,10 484,20 515,60 0,00
EBITDA1,2 86,60 13,00 35,20 30,50 28,30 -16,10 0,00
EBITDA-Marge3 15,66 3,44 8,79 7,28 5,84 -3,12 0,00
EBIT1,4 63,90 -9,30 10,60 -1,20 -1,30 -47,10 0,00
EBIT-Marge5 11,55 -2,46 2,65 -0,29 -0,27 -9,14 0,00
Jahresüberschuss1 -45,70 -3,50 181,70 -4,70 -31,40 -63,40 0,00
Netto-Marge6 -8,26 -0,93 45,39 -1,12 -6,48 -12,30 0,00
Cashflow1,7 65,90 34,30 -50,00 -33,60 -16,70 33,90 0,00
Ergebnis je Aktie8 -1,17 -0,40 4,58 -0,11 -0,72 1,59 -0,35
Dividende8 0,07 0,04 0,04 0,04 0,04 0,04 0,04
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Biotest VZ
WKN Kurs in € Einschätzung Börsenwert in Mio. €
522723 33,400 Halten 1.501,74
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
51,38 21,06 2,44 -547,54
KBV KCV KUV EV/EBITDA
3,48 38,99 2,91 -116,56
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,04 0,04 0,12 05.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
05.05.2022 11.08.2022 14.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,33% -9,08% -13,47% -5,92%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biotest AG  ISIN: DE0005227235 können Sie bei DGAP abrufen


Gesundheit , 522723 , BIO3 , XETR:BIO3